Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 103Carcinoma, Renal Cell 70Neoplasm Metastasis 48Neoplasms 37Neuroendocrine Tumors 33Kidney Neoplasms 27Recurrence 19Tuberous Sclerosis 18Carcinoma, Non-Small-Cell Lung 17Prostatic Neoplasms 16Triple Negative Breast Neoplasms 15Lymphoma 15Lymphoma, Mantle-Cell 14Lymphoma, Large B-Cell, Diffuse 14Head and Neck Neoplasms 14Glioblastoma 14Colorectal Neoplasms 13Carcinoma, Hepatocellular 13Stomach Neoplasms 12Lung Neoplasms 12Leukemia, Lymphocytic, Chronic, B-Cell 12Hodgkin Disease 12Brain Neoplasms 12Sarcoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Glioma 11Waldenstrom Macroglobulinemia 10Lymphoma, Follicular 10Carcinoma, Neuroendocrine 10

Interventions

Propranolol 8Timolol 5Prednisolone 4Prednisone 3Adrenergic beta-Antagonists 3Solutions 2Saline Solution 2Methylprednisolone 2Adrenal Cortex Hormones 2prednisolone phosphate 1Vincristine 1Tomography, Optical Coherence 1Steroids 1Sodium Chloride 1Sirolimus 1Population Groups 1Ointments 1Nadolol 1Mupirocin 1Leuprolide 1Lasers, Semiconductor 1Lasers, Dye 1Imiquimod 1Gels 1Everolimus 1Bleomycin 1Atenolol 1Acebutolol 168Ga-1,4,7-triazacyclononane-N,N',N''-triacetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hemangioma × Everolimus × Clear all
NCT07477548 2026-03-17

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

Yonsei University

Phase 2 Not yet recruiting
67 enrolled

Arteriovenous Malformations, Hemangioendothelioma, Hemangioma, Lymphangioma, Nevus, Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡